Question 1

Is the compounded vial the same drug as the brand?

Accepted Answer

No bioequivalence study of a compounded semaglutide against Wegovy or Ozempic has ever been published, so the size of any difference is unmeasured. What is on record: the brand's 14.9% average loss at 68 weeks comes from STEP-1, against 2.4% on placebo, and no compounded version has been through anything resembling that. Compounded vials are mixed by pharmacies from active ingredient bought from third-party suppliers, sometimes with B vitamins, different preservatives, or buffers the brand does not use. A 2024 analytical study by scientists at Novo Nordisk, the brand's maker, tested follow-on semaglutide and liraglutide products against the originator and found new impurities in the injectable semaglutide, markedly less semaglutide than the label claimed in several oral versions, and less stable liraglutide. Differences like these can change how much active drug a labeled milligram delivers. Plenty of people report the same appetite suppression on compounded, and that counts for something, but it is subjective report and not controlled data.

Question 2

Is compounded semaglutide safe?

Accepted Answer

Safety has never been established to the standard approval requires, and the published signals are strong enough to take seriously. A 2026 analysis of reports to FAERS, the FDA's database of adverse event reports, found compounded GLP-1 agonists reported with higher odds than the brand products for preparation errors, contamination, manufacturing problems and hospitalization, though reports of dosing and administration errors were less common for them. A US poison-control case series described three people harmed by compounded semaglutide: two had injected ten times the intended dose, one needed care at a health facility, and one had measured doses in milliliters and units instead of milligrams. A separate population-based study found accidental overdose reported disproportionately for every GLP-1 drug, and its authors linked that partly to people buying from online and compounding pharmacies. The signal points at how the product is made, packaged and measured, not at semaglutide itself. So the practical answer is about format. Treat a multi-dose vial with the caution any unapproved injectable deserves, and see the dosing-error question below.

Question 3

What do 503A and 503B actually mean?

Accepted Answer

Two legal categories under the Food, Drug, and Cosmetic Act, and knowing which one filled your vial tells you more than anything else on the pharmacy's website. The difference is who is watching. A 503A pharmacy works prescription by prescription for a named patient, answers mainly to its state board, sits outside the Current Good Manufacturing Practice regime, and cannot batch commercial-equivalent drugs for office stock. An outsourcing facility under 503B is the opposite on each count: registered with the FDA itself, subject to its inspections, operating under CGMP, obliged to file adverse-event reports, and permitted to produce batches that prescribers stock. In practice the gap shows up in testing, meaning how often sterility, endotoxin and potency are checked. A 2026 analysis of how hospitals should source an injectable drug during an FDA-reported shortage concluded that a 503B facility, with its CGMP duties and stricter FDA oversight, is the safer route. For semaglutide and tirzepatide that comparison now covers only the shortage years: FDA says outsourcing facilities may not compound either drug from bulk, and their grace periods ended in 2025, so a seller who answers "503B" today should explain how. Ask which tier yours is registered under and get it in writing; do not infer it from a homepage.

Question 4

Is compounded weaker than the brand?

Accepted Answer

No peer-reviewed potency comparison exists for any specific compounded product against Wegovy, Ozempic, Mounjaro or Zepbound, so this cannot be answered definitively for your vial. What is documented: the 2024 analytical work on follow-on GLP-1 products found impurities the originator did not have, oral versions holding markedly less semaglutide than their labels claimed, and liraglutide copies more prone to clumping, each capable of shifting effective potency at an identical labeled milligram. The brand benchmarks to compare against are semaglutide 2.4 mg at about 14.9% over 68 weeks in STEP-1, and tirzepatide 15 mg at about 20.9% over 72 weeks in SURMOUNT-1. If a compounded lot runs under its labeled potency, real-world loss can fall short of those numbers at what looks like the same dose. When results stall after months of a good response, the candidates are a weaker lot, lifestyle drift, or a real plateau, and only the lot question can be settled, by trying the brand.

Question 5

Why did my side effects get worse on brand?

Accepted Answer

Usually because you are now getting more active drug than you were used to, not because the brand is harsher. Brand doses are milligrams of fully active peptide made under CGMP; if the compounded lot was running below its labeled potency, the matching brand dose delivers a real step up. The FDA's own position is that a compounded product can vary in strength against the approved one. That is why matching the milligram number from your compounded vial is the wrong move. Begin on the brand's starting dose, 0.25 mg for semaglutide or 2.5 mg for tirzepatide, and climb in the label's four-week steps, which is the schedule the trials validated for tolerability. Pooled tolerability data across SURMOUNT shows the stomach symptoms cresting whenever the dose moves up and easing while it stays put, so a rough first month is not a signal to abandon the switch. Agree on the starting dose with your prescriber before the first injection.

Question 6

Is compounded semaglutide still legal now the shortage is over?

Accepted Answer

The rules turn on the FDA shortage list, and both drugs are off it: tirzepatide since December 19, 2024, semaglutide since February 21, 2025. Once a drug leaves that list, a 503A pharmacy is generally barred from making copies of it, and the transition windows the FDA allowed after each resolution have passed. What survives is narrower than people assume. It covers a strength, route or excipient combination that is unavailable commercially and clinically justified for one named patient, and not a like-for-like copy at a better price. Compounder litigation has followed and state boards differ, so what is available to you depends on your state and your pharmacy. If you are filling a 503A prescription through a telehealth service today, ask the prescriber to record in your chart why the personalized formulation is clinically necessary. Check the FDA shortage portal yourself rather than trusting a seller's claim about it.

Question 7

Will insurance ever cover the compounded version?

Accepted Answer

Only in narrow cases, going by the plan rules that are public. FDA says compounded drugs are not FDA-approved, and insurers' compound policies are written around that. Cigna's says bulk chemicals do not meet its standard plans' definition of a prescription drug and that all benefit exclusions still apply. The Federal Employee Program's does not cover a compound when the dosage form and strength are commercially available or when no FDA-approved indication supports the use. We found no carrier document that names compounded GLP-1s specifically, so your own plan's booklet is what counts. A missing billing code is only part of it: FDA's National Drug Code directory lists compounded products from outsourcing facilities that chose to assign codes, and a code would not get a claim past those rules. The brands can be covered wherever a plan funds obesity or diabetes drugs at all, though you should expect prior authorization, a BMI threshold and evidence of documented lifestyle effort. Check the cash route before assuming compounded is cheaper. The manufacturers' direct-pay vial programs frequently beat a compounded price once a telehealth membership fee is counted, and the seller quoting you a monthly figure has no reason to make that comparison. Have your prescriber file the prior authorization properly instead of assuming the answer in advance.

Question 8

How should I move from compounded back to brand?

Accepted Answer

Restart at the bottom. No randomized trial covers this transition, but the standard approach is the lowest brand starting dose and the full label titration: Wegovy 0.25 mg weekly for four weeks before any increase, or Zepbound 2.5 mg weekly for four weeks. The reason is the same one behind the side-effect question above. A compounded lot may have been delivering less, or occasionally more, active peptide than its label said, so the milligram number you were on is not a reliable guide to what you are acclimated to. Four weeks per step is the schedule STEP-1 and SURMOUNT-1 ran, and the pooled SURMOUNT tolerability analysis confirms symptoms peak at each escalation and then ease. People also report a few practical habits. Pick an injection day with nothing that has to go right, keep bland high-protein food in the house for the first few days, and do not stack a diet change onto the same week. Plan the restart with your prescriber rather than self-titrating.

Question 9

My source is shutting down. Can I move from tirzepatide to semaglutide?

Accepted Answer

People do it, but go in expecting less, not more. No trial has studied switching between compounded products; the closest evidence is the brand head-to-head, SURMOUNT-5, which put tirzepatide at about 20.2% against semaglutide at about 13.7% at 72 weeks, roughly 6.5 percentage points apart in tirzepatide's favor. Switching from tirzepatide to semaglutide means moving toward the smaller number. There is no conversion between them, because they are different kinds of drug: tirzepatide works on both the GIP and GLP-1 receptors, semaglutide only on GLP-1. Most prescribers restart semaglutide at 0.25 mg weekly and titrate normally regardless of the tirzepatide dose you were on. Expect the switch to feel like starting over, with stomach symptoms peaking in the first week or two of each new dose and easing across the following month. Talk to your prescriber before changing molecule, not after the first injection.

Question 10

Are the dosing-error warnings real, or is the FDA overreacting?

Accepted Answer

Real, and documented in the peer-reviewed literature, not only in FDA messaging. A US poison-control case series described three people who fell ill after mis-dosing semaglutide from compounding pharmacies or a spa. Two injected ten times the intended dose, and one had been measuring in milliliters and units when the dose was meant in milligrams. A pharmacovigilance analysis of the FDA's adverse event system found compounded GLP-1s reported with higher odds than the brand products for preparation and prescribing errors and for hospitalization, though dosing errors were reported less often for them. A population-based study found accidental overdose reported disproportionately across the whole GLP-1 class and tied part of it to online and compounding sources. The cause is mechanical, not chemical. A brand pen arrives with the dose already set, or as a vial holding exactly one; the typical 503A product is a multi-dose vial at a non-standard strength, leaving you to measure each dose yourself. That makes the risk reducible. Have the pharmacy label in micrograms or milligrams rather than mL alone, and re-read the strength on each new vial, because refills do not always arrive at the strength the last one had.

Compounded or Brand: the 10 Questions Patients Keep Asking

Q1.Is the compounded vial the same drug as the brand?

Q2.Is compounded semaglutide safe?

Q3.What do 503A and 503B actually mean?

Q4.Is compounded weaker than the brand?

Q5.Why did my side effects get worse on brand?

Q6.Is compounded semaglutide still legal now the shortage is over?

Q7.Will insurance ever cover the compounded version?

Q8.How should I move from compounded back to brand?

Q9.My source is shutting down. Can I move from tirzepatide to semaglutide?

Q10.Are the dosing-error warnings real, or is the FDA overreacting?

References

Questions and answers